This is the authors' abstract. We don't add key points for this paper.
Key Points A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations. A short course of daratumumab is a novel treatment of refractory thrombocytopenia after failure of standard treatment options.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Migdady et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: